Teneligliptin: DPP-4 inhibitor in the treatment of type II Diabetes Mellitus

K. R. Danao, M. V. Shende, R. A. Gupta, N. G. Dumore, U. N. Mahajan


The collective review of teneligliptin as an antidibetic drug concerning about the mechanisms of action, pharmacokinetic study, pharmacodynamic study, toxicological study and dose and its contraindication. Teneligliptin is used in the treatment of type II diabetes mellitus. Teneligliptin, a third generation DPP-4 inhibitor, teneligliptin was approved by the US Food and Drug Administration on 2012 based on a large development program. Teneligliptin, a novel DPP-4 inhibitor, exhibits a unique structure characterized by five consecutive rings, which produce a potent and long-lasting effect.  Teneligliptin is currently used in cases showing insufficient improvement in glycemic control even after diet control and exercise or a combination of diet control, exercise, and sulfonylurea or thiazolidine-class drugs.  In adults, teneligliptin is orally administered at a dosage of 20 mg once daily, which can be increased up to 40 mg per day. Due to the metabolites of this drug are eliminated via renal and hepatic excretion so, adjustable dose is not required to renal impairment patient. In this review, all the clinical data is described. Teneligliptin shows promise in stabilizing glycemic fluctuations throughout the day and consequently suppressing the progression of diabetic complications.


Teneligliptin, DPP-4 inhibitor, hypoglycemic, toxicity

Full Text:



. Ideta T., Shirakami Y., Miyazaki T., Kochi T., Sakai H., Moriwaki H., Shimizu M., Int. J. Mol. Sci. 2015; 16: 29207–29218.

. Bhatia M., CIMS speciailty information booklet, UBM medica Publisher of CIMS/IDR, 2015; 2-16.

. Kharkar S., Zika Virus: A Review for Clinicians. Vidarbha Journal of Internal Medicine, 2016; 21: 34-36.

. Nabeno M., Akahoshi F., Kishida H., Miyaguchi I., Tanaka Y., Ishii

S., A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochemical and Biophysical Research Communications. 2013; 434: 191-196.

. Inoue E., Kadowaki S., Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2012; 14(11): 1040-6.

. Tanaka S., Suzuki K., Aoki C., Niitani M., Kato K., Tomotsune T., Remote Glucose Monitoring in Camp Setting Reduces the Risk of Prolonged Nocturnal Hypoglycemia. Diab Tech & Ther. 2014; 16:1-8.

. Goda M., Kadowaki T., Teneligliptin for the treatment of type 2 diabetes. Drugs of Today 2013; 49(10): 615-629.

. Shivashankar M., Mani D. A., A brief overview of diabetes. Int J Phar Pharm Sci 2011; 3(4):22-27.

. Dicker D., DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes care 2011; 34(2): 276-278.

. Maladkar M., Sankar S., Kamat K., Teneligliptin: Heralding Change in Type 2 Diabetes. Journal of Diabetes Mellitus, 2016; 6: 113-131.

. Grafe-Mody E.U., Rose P., Retlich S., Ring A., Waldhauser L., Cinca R., Woerle H.J., Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br. J. Clin. Pharmacol., 2012; 74: 75-85.

. Horie Y., Kanada S., Watada H., Sarashina A., Taniguchi A., Hayashi N., Graefe E.U. - Mody, H.J. Woerle, K.A. Dugi, Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients. Clin. Ther. 2011; 33: 973-989.

. Graefe-Mody E.U., Jungnik A., Ring A., Woerle H.J., Dugi K.A., Pharmacokinetics of linagliptin in subjects with hepatic impairment. Int. J. Clin. Pharmacol. Ther. 2010; 48: 652-661.

. Heise T., Graefe-Mody E.U., Hüttner S., Ring S., Trommeshauser D., Dugi K.A., Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes, Obes. Metab., 2009; 11: 786-794.

. Graefe-Mody E.U., Padula S., Ring A., Withopf B., Dugi K.A., Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr. Med. Res. Opin., 2009; 25: 1963-1972.

. Graefe-Mody E.U., Retlich S., Friedrich C., Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus Clin. Pharmacokinet., 2012; 51: 411-427.

. Friedrich C., Glund S., Lionetti D., Kissling C.J., Righetti J., Patel S., E.U. Graefe-Mody, Retlich S., Woerle H.J., Br. J. Clin. Pharmacol., 2013; 76: 445-454.

. Retlich S., Duval V., Graefe-Mody U., Friedrich C., Patel S., Jaehde U., Staab A., Clin. Pharmacokinet., 2015; 54: 737-750.

. Sekhar C.K., Sudhakar P., Rao T.M., Babu P.V., Manikanta K.A., Int. J. Univers. Pharm. Bio Sci., 2013; 2: 1-6.

. Kalra S., Das A.K., Sahay R., Managing diabetes: The drivers of change. Journal of Social Health & Diabetes, 2013; 1: 3-5.

. Kalra S, Recent Advances in Pathophysiology of Diabetes: Beyond the Dirty Dozen. Journal of Pakistan Medical Association, 2013; 2: 277-280.

. Baetta. R., Corsini, A., Pharmacology of Dipeptidyl Peptidase-4 Inhibitors. Drugs, 2011; 71: 1441-1467.

. Drucker,D.J. Nauck M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet, 2006; 368: 1696-1705.

. Verspohl E.J., Novel therapeutics for type 2 diabetes: incretin hormone mimetics. Pharmacology & Therapeutics, 2009; 124: 113-138.

. Nabeno, M., Akahoshi, F., Kishida H., Miyaguchi I., Tanaka. Y, Ishii S, Kadowaki T. Teneligliptin: Heralding Change in Type 2 Diabetes. Biochemical and Biophysical Research Communications, 2013; 434: 191-196.

. Kushwaha R.N., Haq, W. , Katti. S.B. Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: a perspective. Chemistry & Biology Interface, 2014; 4: 137-162.

. Röhrborn D., Wronkowitz N., Eckel J. DPP4 in Diabetes. Frontiers in Immunology, 2015; 6: 1-20.

. Kishimoto M., Diabetes, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. Metabolic Syndrome and Obesity: Targets and Therapy, 2013; 6: 187-195.

. Kadowaki T, Kondo, K., Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase‐4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24‐week multicentre randomized, double‐blind, placebo‐controlled phase III trial. Diabetes, Obesity and Metabolism, 2013; 15: 810-818.

. Kutoha E, Hiratea M., Ikenoa Y., Teneligliptin: Heralding Change in Type 2 Diabetes, Journal of Clinical Medicine Research, 2014; 6: 287-294.

. Suh S., Kim J.H., Glycemic Variability: How Do We Measure It and Why Is It Important? Diabetes & Metabolism Journal, 2015; 39: 273-282.

. Marling C.R., Shubrook H.J., Vernier S.J., Wiley M.T., Schwartz F.L., Characterizing Blood Glucose Variability Using New Metrics with Continuous Glucose Monitoring Data. Journal of Diabetes Science and Technology, 2011; 5: 871-878.

. Furusyo N., Hayashi J., Glycated Albumin and Diabetes Mellitus. Biochimica et Biophysica Acta, 2013; 1830: 5509-5514.

. Dąbrowska A.M., Tarach J.S., Kurowska M., Medical and Biological Sciences, 2012; 26: 11-17.

. Watanabe M., Kokubo Y., Higashiyama A., Atherosclerosis, 2011; 216: 477-483.

. Ceriello A., Quagliaro L., Piconi L., Assaloni R., Daros R., Maier A., Esposito K., Giugliano D., Diabetes, 2004; 53: 701-710.

. Kawano H., Motoyama T., Hirashima O., Hirai N., Miyao Y., Sakamoto T., Kugiyama K., Ogawa H., Yasue H., Journal of the American College of Cardiology, 1999; 34: 146-154.

. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P.,Colette C., The Journal of American Medical Association, 2006; 295: 1681-1687.

. Goda M., Kadowaki T., Drugs of Today, 2013; 49: 615-629.

. Tanaka S., Suzuki K., Aoki C., Niitani M., Kato K., Tomotsune T., Aso Y., Diabetes Technology & Therapeutics, 2014; 16: 840-845.

. Nakamaru Y., Hayashi Y., Ikegawa R., Kinoshita S. Madera B.P., Gunput D., Xenobiotica, 2014; 44: 242-253.

. Nakamaru Y., Hayashi Y., Sekine M., S. Kinoshita, J. Thompson,, A. Kawaguchi, Clinical Therapeutics, 2014; 36: 760-769.

DOI: http://dx.doi.org/10.7439/ijpp.v7i4.4347

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


  • There are currently no refbacks.

Copyright (c) 2017 International Journal of Phytopharmacy

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.